Aligos Therapeutics (ALGS) Accumulated Depreciation & Amortization (2021 - 2025)
Historic Accumulated Depreciation & Amortization for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $12.5 million.
- Aligos Therapeutics' Accumulated Depreciation & Amortization rose 791.96% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 791.96%. This contributed to the annual value of $11.8 million for FY2024, which is 954.9% up from last year.
- Latest data reveals that Aligos Therapeutics reported Accumulated Depreciation & Amortization of $12.5 million as of Q3 2025, which was up 791.96% from $12.2 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Accumulated Depreciation & Amortization registered a high of $12.5 million during Q3 2025, and its lowest value of $5.0 million during Q1 2021.
- For the 5-year period, Aligos Therapeutics' Accumulated Depreciation & Amortization averaged around $9.7 million, with its median value being $10.4 million (2023).
- In the last 5 years, Aligos Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 5924.96% in 2022 and then skyrocketed by 496.98% in 2025.
- Quarter analysis of 5 years shows Aligos Therapeutics' Accumulated Depreciation & Amortization stood at $7.3 million in 2021, then skyrocketed by 31.75% to $9.6 million in 2022, then grew by 12.41% to $10.8 million in 2023, then grew by 9.55% to $11.8 million in 2024, then rose by 5.71% to $12.5 million in 2025.
- Its Accumulated Depreciation & Amortization was $12.5 million in Q3 2025, compared to $12.2 million in Q2 2025 and $12.0 million in Q1 2025.